Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helsinn Healthcare SafiledCriticalHelsinn Healthcare Sa
Publication of GT201700041ApublicationCriticalpatent/GT201700041A/en
SE DESCRIBEN MÉTODOS DE TRATAMIENTO DE AFECCIONES RELACIONADAS CON EL CÁNCER USANDO ANAMORELINA. LA MODALIDAD PRINCIPAL SE RELACIONA CON LA AFECCIÓN ÚNICA DE PACIENTES QUE LA DEFINEN MEDIANTE EL TRATAMIENTO DE LA CAQUEXIA EN UN PACIENTE HUMANO CON CÁNCER, QUE COMPRENDE LA ADMINISTRACIÓN A DICHO PACIENTE DE UNA CANTIDAD TERAPÉUTICAMENTE EFECTIVA DE ANAMORELINA DURANTE UN PERÍODO TERAPÉUTICAMENTE EFECTIVO, Y LA SORPRENDENTE CAPACIDAD OBSERVADA DE LA ANAMORELINA DE AUMENTAR LA MASA CORPORAL MAGRA DE ESTA POBLACIÓN.METHODS OF TREATMENT OF AFFECTIONS RELATED TO CANCER USING ANAMORELINE ARE DESCRIBED. THE MAIN MODALITY IS RELATED TO THE SINGLE AFFECTION OF PATIENTS DEFINING THEM BY MEANS OF THE TREATMENT OF CAQUEXY IN A HUMAN PATIENT WITH CANCER, WHICH UNDERSTANDS THE PATIENT ADMINISTRATION OF A THERAPEUTICALLY EFFECTIVE AMOUNT OF THE NON-PERFORMALLY PERFORMANTLY NORMAL PERFORMANCE. OBSERVED CAPACITY OF ANAMORELINE TO INCREASE THE MAGRA BODY MASS OF THIS POPULATION.
GT201700041A2014-09-042017-03-02
ANAMORELINE BASED MEDICAL TREATMENTS
GT201700041A
(en)
APPLICATION OF THE COMBINATION OF ANGIOTENZINE-TURNING ENZYME INHIBITOR AND EPIPHYSIS HORMONE FOR TREATMENT OF ISCHEMIC HEART DISEASE IN ELDERLY PATIENTS